 GAINESVILLE, Fla.--BUSINESS WIRE--Cyclo Therapeutics, Inc. Nasdaq: CYTH Cyclo Therapeutics or the Company, a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced new data from its Phase 1 extension study evaluating Trappsol CycloTM for the treatment of Niemann-Pick Disease Type C1 NPC, a rare, progressive and fatal genetic disorder characterized by abnorma 